Pascal Touchon | President, Chief Executive Officer And Board Member
Atara Biotherapeutics

Pascal Touchon, President, Chief Executive Officer And Board Member, Atara Biotherapeutics

Dr. Touchon joined Atara Biotherapeutics as President, Chief Executive Officer and member of the Board of Directors in June 2019. Dr. Touchon has over 30 years of global biopharmaceutical leadership experience. Previously he was at Novartis Oncology serving as Global Head, Cell & Gene and member of the Oncology Executive Committee, with responsibility for the Oncology Cell & Gene unit financial performance and all activities including the global launch of KYMRIAH® (tisagenlecleucel), securing regulatory approval and reimbursement in major markets, expanding global CAR T manufacturing and technical operations, overseeing multiple new clinical studies and building a strong leadership team.

Prior to this, at Novartis he served as Global Head, Strategy, Business Development, Oncology where he was responsible for various activities including early commercial strategy, portfolio management, business development and external collaborations as well as member of the Oncology Executive Committee. Dr. Touchon has also held leadership roles in research, marketing, general management and business development at various companies including Servier, Sanofi, Glaxo and Glaxo-Wellcome.

Dr. Touchon holds a Doctorate in Veterinary Medicine from Paul Sabatier University (Toulouse, France), a Diplôme d’Etudes Superieures Specialisees (DESS) in Management from Institut d’Administration des Entreprises (Toulouse, France) and an MBA from INSEAD (Fontainebleau, France).

Appearances:



Conference Day 1 - Tuesday 31st March 2020 @ 09:20

Realizing the promise of ATMPs for patients around the world

  • Working with regulators to navigate scale up challenges in manufacturing
  • Strategies in supply chain and patient delivery
  • Tackling post manufacturing commercialization challenges such as pricing and finding highly skilled experts
  • Durability
last published: 05/Dec/19 09:46 GMT

back to speakers